Literature DB >> 22544415

Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy.

Christopher M Huff1, Aslan T Turer, Andrew Wang.   

Abstract

BACKGROUND: Dyspnea and the resulting functional impairment are a common complication in hypertrophic cardiomyopathy (HCM). The relationship between physician-perceived functional status, patient-perceived health status, and objective exercise test results has not been evaluated in this condition.
PURPOSE: To evaluate the correlation between the Kansas City Cardiomyopathy Questionnaire (KCCQ) and (1) physician's perceived (NYHA class) and (2) objective measurement (cardiopulmonary exercise test) of functional capacity in patients with HCM.
METHODS: In 24 outpatients with HCM at a single, referral center, the KCCQ instrument was administered and cardiopulmonary exercise testing (CPX) was performed. Severity of symptoms as determined by physician (NYHA classification) and patient (KCCQ instrument) was obtained before exercise test results were known. Pearson correlation was used to assess the independent correlation between KCCQ score and the various exercise parameters; Spearman correlation was used to assess correlation between KCCQ score and NYHA class.
RESULTS: KCCQ results demonstrated moderate reductions in all domains, with greatest reduction in quality-of-life domain. CPX testing showed reduction in peak oxygen consumption (mean absolute VO2 20.5 ± 7.8 ml/kg/min and percent predicted VO2 76.8 ± 4.1 %). There were negative correlations between NYHA class and all KCCQ components except the self-efficacy score. The strongest correlations were between NYHA class and the overall summary score (r = -0.623, p = 0.001) as well as the physical limitation score (r = -0.604, p = 0.002). Similarly, there were statistically significant positive correlations between the KCCQ components and percent predicted peak VO2. The strongest correlation was between percent predicted peak VO2 and the physical limitation score (r = 0.474, p = 0.019), but there was also correlation between percent predicted peak VO2 and the quality-of-life score (r = 0.456, p = 0.025), the functional status score (r = 0.455, p = 0.025), and the clinical summary score (r = 0.444, p = 0.030).
CONCLUSIONS: The multiple domains of the KCCQ provide data on patient-perceived health status, which correlate with physician-perceived and objective measurement of functional capacity in HCM. Additional studies are needed to evaluate the sensitivity of the KCCQ to changes in functional capacity over time or in response to therapies for this condition.

Entities:  

Mesh:

Year:  2012        PMID: 22544415     DOI: 10.1007/s11136-012-0182-y

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  16 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison.

Authors:  Ross Arena; Jonathan Myers; Syed Salman Aslam; Elsa B Varughese; Mary Ann Peberdy
Journal:  Am Heart J       Date:  2004-02       Impact factor: 4.749

3.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

4.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial.

Authors:  R A Nishimura; J M Trusty; D L Hayes; D M Ilstrup; D R Larson; S N Hayes; T G Allison; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

5.  Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy.

Authors:  P Boekstegers; P Steinbigler; A Molnar; M Schwaiblmair; A Becker; A Knez; R Haberl; G Steinbeck
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

6.  Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry.

Authors:  Sherif F Nagueh; Bertron M Groves; Leonard Schwartz; Karen M Smith; Andrew Wang; Richard G Bach; Christopher Nielsen; Ferdinand Leya; John M Buergler; Steven K Rowe; Anna Woo; Yolanda Munoz Maldonado; William H Spencer
Journal:  J Am Coll Cardiol       Date:  2011-11-22       Impact factor: 24.094

7.  Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Kathryn E Flynn; Ileana L Piña; David J Whellan; Li Lin; James A Blumenthal; Stephen J Ellis; Lawrence J Fine; Jonathan G Howlett; Steven J Keteyian; Dalane W Kitzman; William E Kraus; Nancy Houston Miller; Kevin A Schulman; John A Spertus; Christopher M O'Connor; Kevin P Weinfurt
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

8.  Pitfalls in the serial assessment of cardiac functional status. How a reduction in "ordinary" activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement.

Authors:  L Goldman; E F Cook; N Mitchell; M Flatley; H Sherman; P F Cohn
Journal:  J Chronic Dis       Date:  1982

9.  Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy.

Authors:  S Jones; P M Elliott; S Sharma; W J McKenna; B J Whipp
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

10.  Assessing responsiveness of generic and specific health related quality of life measures in heart failure.

Authors:  Dean T Eurich; Jeffrey A Johnson; Kimberly J Reid; John A Spertus
Journal:  Health Qual Life Outcomes       Date:  2006-11-24       Impact factor: 3.186

View more
  5 in total

1.  Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Razi Khan; David Massel; John Stirrat; David Scholl; Gerald Wisenberg; Terry Thompson; Maria Drangova; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2012-08-09       Impact factor: 2.357

2.  Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.

Authors:  Sara Saberi; Matthew Wheeler; Jennifer Bragg-Gresham; Whitney Hornsby; Prachi P Agarwal; Anil Attili; Maryann Concannon; Annika M Dries; Yael Shmargad; Heidi Salisbury; Suwen Kumar; Jonathan J Herrera; Jonathan Myers; Adam S Helms; Euan A Ashley; Sharlene M Day
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

3.  Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study.

Authors:  Anjali T Owens; Megan B Sutton; Wei Gao; Jennifer T Fine; Jipan Xie; Srihari S Naidu; Nihar R Desai
Journal:  Cardiol Ther       Date:  2022-03-01

4.  How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?

Authors:  Brandon M Jones; Amar Krishnaswamy; Nicholas G Smedira; Milind Y Desai; E Murat Tuzcu; Samir R Kapadia
Journal:  J Am Heart Assoc       Date:  2017-05-16       Impact factor: 5.501

5.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Authors:  Razvan Capota; Sebastian Militaru; Alin Alexandru Ionescu; Monica Rosca; Cristian Baicus; Bogdan Alexandru Popescu; Ruxandra Jurcut
Journal:  Health Qual Life Outcomes       Date:  2020-10-30       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.